Researchers discovered that respiratory syncytial virus (RSV), a common pathogen causing cold-like symptoms, can paradoxically slow breast cancer spread to the lungs in mice. Scientists infected mice carrying breast cancer with RSV and found the virus triggered the release of interferon proteins that inhibited viral replication. These same interferon proteins simultaneously blocked cancer cells from establishing new tumors in lung tissue.
The mechanism operates through a clever biological overlap. When RSV infects the lungs, immune cells release interferons that create an antiviral environment hostile to viral replication. Cancer cells attempting to metastasize to the lungs encounter this same hostile environment, preventing them from seeding secondary tumors.
This work extends earlier observations that respiratory infections can interfere with metastatic cancer progression. The findings suggest the immune system's antiviral defenses inadvertently create conditions unfavorable for cancer cell colonization of new sites.
The research carries important limitations. The studies involved mice, not humans, and used a specific breast cancer model that may not reflect all cancer types or stages. The benefit appears temporary, lasting only while the viral infection persists. Intentionally infecting cancer patients with RSV would be impractical and dangerous, as respiratory viruses pose their own health risks.
The work does open theoretical pathways for treatment development. Rather than infecting patients with actual viruses, researchers could explore ways to artificially trigger the interferon response without the dangers of active infection. Such approaches might complement existing cancer therapies by creating temporary windows when the lungs become inhospitable to metastatic seeding.
Scientists now plan to investigate whether other respiratory viruses produce similar effects and whether this phenomenon extends to cancers spreading to other organs. Understanding these antiviral-antitumor connections could eventually inform combination therapies that harness immune responses against both infections and cancer.
THE BOTTOM LINE: A common